Live Breaking News & Updates on Cellectis Daily|Page 3
Stay updated with breaking news from Cellectis daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Cellectis S.A. (NASDAQ:CLLS – Get Free Report) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.71 and traded as high as $2.82. Cellectis shares last traded at $2.75, with a volume of 20,196 shares trading hands. Cellectis Stock Up 0.4 […] ....
Cellectis S.A. (NASDAQ:CLLS – Get Free Report)’s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.99 and traded as low as $2.65. Cellectis shares last traded at $2.72, with a volume of 78,666 shares changing hands. Wall Street Analyst Weigh […] ....
Baillie Gifford & Co. decreased its holdings in shares of Cellectis S.A. (NASDAQ:CLLS – Free Report) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,418,996 shares of the biotechnology company’s stock after selling 220,900 shares during the quarter. Baillie Gifford […] ....
Baillie Gifford & Co. trimmed its stake in shares of Cellectis S.A. (NASDAQ:CLLS – Free Report) by 13.5% during the second quarter, HoldingsChannel.com reports. The firm owned 1,418,996 shares of the biotechnology company’s stock after selling 220,900 shares during the quarter. Baillie Gifford & Co.’s holdings in Cellectis were worth $2,795,000 as of its most […] ....
StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report issued on Tuesday. The firm issued a hold rating on the biotechnology company’s stock. A number of other analysts have also commented on the stock. JMP Securities restated a market outperform rating and set a $6.00 price target on shares of […] ....